Thyroid autoimmunity following alemtuzumab treatment in multiple sclerosis patients: a prospective study.

MLA

Kazakou, Paraskevi, et al. “Thyroid Autoimmunity Following Alemtuzumab Treatment in Multiple Sclerosis Patients: A Prospective Study.” Clinical and Experimental Medicine, vol. 23, no. 6, Oct. 2023, pp. 2885–94. EBSCOhost, https://doi.org/10.1007/s10238-022-00981-3.

APA

Kazakou, P., Tzanetakos, D., Vakrakou, A. G., Tzartos, J. S., Evangelopoulos, Μ.-E., Anagnostouli, M., Stathopoulos, P., Kassi, G. N., Stefanis, L., Kilidireas, C., & Zapanti, E. (2023). Thyroid autoimmunity following alemtuzumab treatment in multiple sclerosis patients: a prospective study. Clinical and Experimental Medicine, 23(6), 2885–2894. https://doi.org/10.1007/s10238-022-00981-3

Chicago

Kazakou, Paraskevi, Dimitrios Tzanetakos, Aigli G Vakrakou, John S Tzartos, Μaria-Eleptheria Evangelopoulos, Maria Anagnostouli, Panos Stathopoulos, et al. 2023. “Thyroid Autoimmunity Following Alemtuzumab Treatment in Multiple Sclerosis Patients: A Prospective Study.” Clinical and Experimental Medicine 23 (6): 2885–94. doi:10.1007/s10238-022-00981-3.